Intelligence · Clinical Pipeline
Nektar Therapeutics UK Pipeline
All ClinicalTrials.gov programs at Nektar Therapeutics UK — phase, modality, and trial IDs.
- Programs
- 11
Quick answer
Nektar Therapeutics UK has 11 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
Amikacin Inhalation Solution (BAY41-6551)
Nektar Therapeutics UK Limited
Pneumonia, Bacterial
1 trial -
Bempegaldesleukin
Nektar Therapeutics UK Limited
Melanoma
1 trial -
Bempegaldesleukin
Nektar Therapeutics UK Limited
Metastatic Head and Neck Cancer
1 trial -
Inhaled Human Insulin
Nektar Therapeutics UK Limited
Diabetes Mellitus, Type 2
1 trial -
NKTR-102
Nektar Therapeutics UK Limited
Locally Recurrent Breast Cancer
1 trial -
NKTR-102
Nektar Therapeutics UK Limited
Metastasis
1 trial -
NKTR-181 BID tablets
Nektar Therapeutics UK Limited
Low Back Pain
2 trials -
NKTR-214
Nektar Therapeutics UK Limited
Melanoma
1 trial -
NKTR-255 at 1.5 µg/kg
Nektar Therapeutics UK Limited
Non-Hodgkin Lymphoma
1 trial -
Nivolumab
Nektar Therapeutics UK Limited
Bladder Cancer
1 trial -
bempegaldesleukin
Nektar Therapeutics UK Limited
Renal Cell Carcinoma
1 trial
Frequently asked questions
How many pipeline programs does Nektar Therapeutics UK have?
11 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs